AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05683119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and blood draw
Description: This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
Study NCT04339699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NobleStitch™EL Suture Mediated Closure System
Description: Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
Study NCT04339699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amplatzer PFO Occluder
Description: Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
Study NCT05578599 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Swiftsure CCS device
Description: The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
Study NCT05706584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control grup (skills lab.) and experimental group (mateverse skill lab.)
Description: The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
Study NCT05405738 — intervention group
Intervention type: PROCEDURE
Intervention: 2 flap palatoplasty technique
Description: cleft palate repair by 2 flap palatoplasty technique
Study NCT05405738 — intervention group
Intervention type: OTHER
Intervention: normal group
Description: control normal group
Study NCT04785274 — intervention group
Intervention type: DEVICE
Intervention: non-invasive hemoglobin (SpHb)
Description: hemoglobin measuring device
Study NCT05678556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: all2GETHER
Description: all2GETHER is an HIV prevention and relationship education program designed for young MSM and other individuals who have sex, date, and are in relationships with MSM. all2GEHTER consists of 3 online didactic skills modules that include videos, activities, and other self-paced education components and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV and STI prevention in couples, effective communication skills, coping skills for LGBTQ and relationship stress, problem-solving and acceptance. Individualized couple sessions led by facilitators focus on implementation of skills specific to the needs of each couple.
Study NCT04909775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg per cycle, IV on day 1 of 3-week
Study NCT04909775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
Study NCT04909775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
Study NCT05096507 — intervention group
Intervention type: PROCEDURE
Intervention: Hip fracture Surgery (Primary)
Description: Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
Study NCT05405738 — intervention group
Intervention type: PROCEDURE
Intervention: Furlow with buccinator technique
Description: cleft palate repair by Furlow with buccinator technique
Study NCT04694313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPM
Description: Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
Study NCT06593418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT
Study NCT05284344 — intervention group
Intervention type: DRUG
Intervention: Anti-Diabetics
Description: The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
Study NCT06624696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Description: The penehyclidine hydrochloride will be diluted to a total volume of 5 mL with normal saline, added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
Study NCT06624696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
Study NCT04841577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
Study NCT04841577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA investigational vaccine
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
Study NCT04841577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLU-QIV
Description: FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
Study NCT05562609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Ampoules and packaging for all arms will be identical in appearance.
Study NCT05562609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Ampoules and packaging for all arms will be identical in appearance.
Study NCT05562609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ampoules and packaging for all arms will be identical in appearance.
Study NCT06757725 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: colour doppler of the renal artery and measurement of resistive index
Description: using colour doppler to asses vascular resistance and resistive index
Study NCT06756711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A combination of apitherapy and plant extracts
Description: This combination contains the active comparator
Study NCT06756711 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Combination
Description: A combination containing inert substances - placebo
Study NCT06757153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRG-103
Description: NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.
Study NCT06757179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elysium Naso Gola
Description: Elysium Naso Gola Supplement is a dietary supplement designed to soothe the upper respiratory tract, providing a range of benefits thanks to the properties of its natural ingredients. Its anti-inflammatory, antibacterial, antifungal, antiviral, antioxidant, and prebiotic activities suggest a comprehensive product for supporting respiratory health.~Mullein promotes the functionality of the respiratory mucous membranes. Thyme supports nasal and throat well-being, aids in the fluidity of bronchial secretions, and has antioxidant properties.
Study NCT06757179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06756828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 3months melatonin
Study NCT06756828 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy group for insomnia
Description: 15minutes of sleep hygiene education on the first day of visiting the hospital
Study NCT06756841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEF treatment
Description: PEF energy delivery via endoscope
Study NCT05562609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ampoules and packaging for all arms will be identical in appearance.
Study NCT06757790 — intervention group
Intervention type: OTHER
Intervention: A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
Description: A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
Study NCT06756932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-21447
Description: Administered orally.
Study NCT06756932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered via intramuscular injection.
Study NCT06756932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Administered orally.
Study NCT04841577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU-QIV
Description: FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
Study NCT04891003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
Study NCT06630000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT
Description: Two 90-minute FACT sessions led by a trained interventionist.
Study NCT06630000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Two 90-minute sessions individually with a study interventionist, 2-weeks apart (focused on nutrition education).
Study NCT04944901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-121
Description: SB-121 is a formulation of L. reuteri
Study NCT04944901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral formulation
Study NCT05562609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ampoules and packaging for all arms will be identical in appearance.
Study NCT06356389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX11502MA
Description: Oral capsule
Study NCT06356389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT06287398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab (Epcor) is a bispecific antibody recognizing the T-cell antigen CD3 and the B-cell antigen CD20. Epcor is a supplied as a concentrate for solution for intended subcutaneous injection. The dose must be prepared by a qualified pharmacist using aseptic technique.~Epcoritamab-Salvage treatment phase:~2-3 cycles of R-DHAOx therapy (rituximab, dexamethasone, cytarabine, oxaliplatin), given every 21 days combined with Epcoritamab subcutaneous weekly dosing (priming 0.16mg Cycle 1 Day 1, intermediate 0.8mg cycle 1 day 8, full dose 48mg from cycle 1 day 15 onwards)~Epcoritamab Consolidation phase:~6 cycles (28 days each) of subcutaneous Epcoritamab, commencing between 6-12 weeks post ASCT.~Epcoritamab dosing and timing for consolidation:~* Cycle 1 Day 1: Priming (0.16mg) dose~* Cycle 1 Day 8: intermediate (0.8mg) dose~* Cycle 1 Day 15: full dose 48mg~* Cycle 1 Day 22, Cycle 2-3 Days 1, 8, 15 and 22: 48mg~* Cycles 4 to 6 - Days 1 and 15 (fortnightly dosing): 48mg
Study NCT04710615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synapse platform
Description: The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication.
Study NCT06471855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Conventional and Technology-based Rehabilitation
Description: Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. According to their individualized rehabilitation project, patients will undergo non-immersive VR-based rehabilitation. VR-based rehabilitation will consist of one daily session (3 weeks) and will be conducted by the implementation of a single non-immersive VR device among the D-WallTM (TechnoBody SRL, Italy), the Walker ViewTM (TechnoBody SRL, Italy). Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants.
Study NCT06471855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary Conventional Rehabilitation
Description: Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to the patient's medical diagnosis, disability severity, and to consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
Study NCT05847114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stres ball
Description: Stress ball compression for 15 minutes during surgery
Study NCT05020314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight Clinic
Description: Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
Study NCT05411939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making Tool
Description: The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
Study NCT05411939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video
Description: Short video that describes knee osteoarthritis and possible treatment options.
Study NCT05411939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Short video that describes knee osteoarthritis and possible treatment options.
Study NCT05411939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care counseling for a patient presenting with knee osteoarthritis.
Study NCT05411939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care counseling for a patient presenting with knee osteoarthritis.
Study NCT06529861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [15O]H2O-PET Imaging
Description: This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.
Study NCT04794075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Education and Nursing Support Program for Supportive Care
Description: In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program.
Study NCT05809362 — intervention group
Intervention type: DEVICE
Intervention: WHOOP 4.0 Strap
Description: Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
Study NCT05809362 — intervention group
Intervention type: DEVICE
Intervention: BioTel ePatch
Description: Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
Study NCT04667104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
Study NCT04667104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally once daily.
Study NCT04667104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF film-coated tablet will be administered orally once daily.
Study NCT04667104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monohydrate
Description: ETV monohydrate film-coated tablet will be administered orally once daily.
Study NCT04667104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha2a
Description: PegIFN-alpha2a injection will be administered subcutaneously once weekly.
Study NCT06183333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heidelberg Emotion Regulation Training
Description: The four-week intervention program is specifically designed to enhance the participants' emotion regulation. It focuses on developing their skills in accurately recognizing various emotions and effectively applying diverse emotion regulation strategies. To achieve this, the program includes video-based psychoeducation sessions. Alongside these sessions, the program incorporates daily short exercises, each lasting approximately five minutes. These exercises are crafted to help participants practically integrate the concepts and strategies learned from the psychoeducation sessions into their everyday lives. All components of the intervention are accessible through an online platform, ensuring ease of access and flexibility for participants.
Study NCT06279507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe
Study NCT06279507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride 2 mL prepared in plastic syringe
Study NCT06279507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: 10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
Study NCT06279507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: 10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention